Back to Dashboard
MDGL · Healthcare

Madrigal Pharmaceuticals Inc

USA Healthcare Filing: 2026-03-31
26/100
Smart-money confidence1 of 3 sources positive
Weak — few signals

company insiders are selling

Hedge funds
50
Congress
No data
Insiders
0
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s.  ·  how the score works
Market cap
$11.9B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About MADRIGAL PHARMACEUTICALS INC

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Who's behind the signal
Every informed buyer we can see on MDGL, across all three feeds.
Hedge funds · 9
Point72 (Steve Cohen) Increased +78%
Citadel Advisors Increased +1156%
Tudor Investment (Paul Tudor Jones) Increased +120%
Millennium Management (Englander) Increased +486%
AQR Capital Management Increased +59%
Paulson & Co (Paulson) Decreased −18%
+3 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
Company insiders Selling
Recent sells41
Not a model pick — but on our radar. MADRIGAL PHARMACEUTICALS INC isn't in the top-10 model right now, but 9 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
9
Investors
0
New positions
5
Increasing
4
Decreasing
0
Unchanged
Price History
Loading price data...
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Point72 (Steve Cohen)
Trust weight: 1.1×
Increased +78%
% of portfolio
0.2%
Position change
+78%
0.2% of Point72's portfolio
Citadel Advisors
Trust weight: 1.0×
Increased +1156%
% of portfolio
0.2%
Position change
+1156%
0.2% of Citadel Advisors's portfolio
Tudor Investment (Paul Tudor Jones)
Trust weight: 1.2×
Increased +120%
% of portfolio
0.0%
Position change
+120%
0.0% of Tudor Investment's portfolio
Millennium Management (Englander)
Trust weight: 1.0×
Increased +486%
% of portfolio
0.0%
Position change
+486%
0.0% of Millennium Management's portfolio
AQR Capital Management
Trust weight: 1.0×
Increased +59%
% of portfolio
0.0%
Position change
+59%
0.0% of AQR Capital Management's portfolio
Paulson & Co (Paulson)
Trust weight: 1.2×
Decreased −18%
% of portfolio
23.4%
Position change
−18%
23.4% of Paulson & Co's portfolio
Alkeon Capital Management
Trust weight: 1.2×
Decreased −67%
% of portfolio
0.2%
Position change
−67%
0.2% of Alkeon Capital Management's portfolio
Bridgewater Associates (Dalio)
Trust weight: 1.3×
Decreased −80%
% of portfolio
0.0%
Position change
−80%
0.0% of Bridgewater Associates's portfolio
D.E. Shaw & Co
Trust weight: 1.0×
Decreased −66%
% of portfolio
0.0%
Position change
−66%
0.0% of D.E. Shaw & Co's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to MADRIGAL PHARMACEUTICALS INC
No insider trades found in the last 90 days
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell MADRIGAL PHARMACEUTICALS INC or any security.

Get the Weekly Update

Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime
© 2026 Bogen Capital  ·  Not financial advice  ·  Data delayed up to 135 days Methodology  ·  Contact  ·  API